Home/ Stocks/ EYPT

EyePoint, Inc. Common Stock

EYPT XNAS

$13.89 +1.16 (+9.07%) ▲ 15-min delayed

Open

$13.04

High

$14.08

Low

$13.03

Volume

1.66M

Market Cap

$1.11B

About EyePoint, Inc. Common Stock

EyePoint Inc focuses is a clinical-stage biopharmaceutical company committed to developing and commercializing therapeutics to improve the lives of patients with serious retinal diseases, that may reduce the frequency of follow-up care. The company's pipeline program includes i) DURAVYU: a sustained-release product candidate for retinal diseases, with the potential to provide patients with improved visual outcomes with less burden. ii) EYP-2301: early-stage program using Durasert E technology to deliver razuprotafib, a TIE-2 agonist targeting VE-PTP for vascular stability in retinal diseases like wet AMD.

Sector: LABORATORY ANALYTICAL INSTRUMENTS Employees: 214 Website →

Key Financials

Period	Revenue	Net Income	EPS
Q2 2026	$507.0K	$-94,470,000	$-1.09
Q1 2026	$696.0K	$-84,832,000	$-0.99
FY 2025	$31.37M	$-231,962,000	$-3.17
Q3 2025	$966.0K	$-59,732,000	$-0.85

Earnings & Analyst Ratings

Next Earnings: Tue, Nov 3, 2026

Calendar →

Related Market News

No specific coverage for EYPT yet. Check out our latest market news or earnings calendar.

Get EYPT Alerts

Stay ahead with breaking news, price alerts, and expert analysis on EyePoint, Inc. Common Stock.

Disclaimer: This page is for informational purposes only. Stock data is delayed by at least 15 minutes. Always conduct your own research and consult with a qualified financial advisor before making investment decisions.